These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors. Qiu LP; Chen L; Chen KP Fundam Clin Pharmacol; 2014 Aug; 28(4):364-81. PubMed ID: 24118072 [TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL; Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260 [TBL] [Abstract][Full Text] [Related]
4. Recent developments in antivirals against hepatitis B virus. Wang YJ; Yang L; Zuo JP Virus Res; 2016 Feb; 213():205-213. PubMed ID: 26732483 [TBL] [Abstract][Full Text] [Related]
5. Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives. Sun D; Zhu L; Yao D; Chen L; Fu L; Ouyang L Eur J Med Chem; 2018 Mar; 147():205-217. PubMed ID: 29438889 [TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis B: Evolution over two decades. Yuen MF; Lai CL J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525 [TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126 [TBL] [Abstract][Full Text] [Related]
8. UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients. De Nicolò A; Simiele M; Pensi D; Boglione L; Allegra S; Di Perri G; D'Avolio A J Pharm Biomed Anal; 2015 Oct; 114():127-32. PubMed ID: 26037161 [TBL] [Abstract][Full Text] [Related]
9. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Férir G; Kaptein S; Neyts J; De Clercq E Rev Med Virol; 2008; 18(1):19-34. PubMed ID: 17966115 [TBL] [Abstract][Full Text] [Related]
10. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues. Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of chronic hepatitis B in HIV co-infected patients]. Massard J; Benhamou Y Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt 2):S20-4. PubMed ID: 18662606 [TBL] [Abstract][Full Text] [Related]
12. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL; J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191 [TBL] [Abstract][Full Text] [Related]
13. Therapy of chronic hepatitis B: trends and developments. Delaney WE; Borroto-Esoda K Curr Opin Pharmacol; 2008 Oct; 8(5):532-40. PubMed ID: 18835366 [TBL] [Abstract][Full Text] [Related]
14. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241 [TBL] [Abstract][Full Text] [Related]
15. Management of chronic hepatitis B virus infection: a new era of disease control. Farrell GC; Teoh NC Intern Med J; 2006 Feb; 36(2):100-13. PubMed ID: 16472264 [TBL] [Abstract][Full Text] [Related]
16. [Prevention and therapy of reactivation of hepatitis B in immunosuppressed patients]. von Wagner M; Zeuzem S Dtsch Med Wochenschr; 2009 Feb; 134(6):255-8. PubMed ID: 19180418 [TBL] [Abstract][Full Text] [Related]
17. Tenofovir for the treatment of hepatitis B virus. Jenh AM; Thio CL; Pham PA Pharmacotherapy; 2009 Oct; 29(10):1212-27. PubMed ID: 19792994 [TBL] [Abstract][Full Text] [Related]
18. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. Leemans WF; Janssen HL; Niesters HG; de Man RA J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193 [TBL] [Abstract][Full Text] [Related]
19. Customizing the management of chronic hepatitis B virus infection. Gish RG; Perrillo RP; Jacobson IM Semin Liver Dis; 2007 Aug; 27 Suppl 1():9-17. PubMed ID: 17701845 [TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]